Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency

. 2017 Feb;23(2):10.18553/jmcp.2017.23.2.214. doi: 10.18553/jmcp.2017.23.2.214

CPT Code	Description
Before 2013^a
83891	Isolation or extraction of highly purified nucleic acid, each nucleic acid type (i.e., DNA or RNA)
83892	Enzymatic digestion, each enzyme treatment
83896	Nucleic acid probe, each 20
83898	Amplification, target, each nucleic acid sequence
83900	Amplification, target, multiplex, first 2 nucleic acid sequences
83901	Amplification, target, multiplex, each additional nucleic acid sequence beyond 2
83902	Reverse transcription
After 2013
81206	BCR/ABL1 (t (9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative
81207	BCR/ABL1 (t (9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative
81208	BCR/ABL1 (t (9;22)) (e.g., chronic myelogenous leukemia) translocation analysis; other breakpoint, qualitative or quantitative

^aSee Appendix B2.

CPT = Current Procedural Terminology; DNA = deoxyribonucleic acid; RNA = ribonucleic acid.